COMMUNIQUÉS West-GlobeNewswire

electroCore Appoints Medical Technology Veteran Daniel S. Goldberger as Chief Executive Officer
30/09/2019
BASKING RIDGE, N.J., Sept. 30, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the appointment of Daniel S. Goldberger as Chief Executive [...]
Cue Biopharma Initiates Patient Dosing in Phase 1 Study of CUE-101 for HPV16-driven Head and Neck Squamous Cell Carcinoma
30/09/2019
CAMBRIDGE, Mass., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate [...]
TYME Presents Supporting Data at ESMO 2019 from TYME-88-Panc Phase II Study Demonstrating Overall Survival Trends, Well Tolerated Safety, and Quality of Life Data in Patients with Advanced Pancreatic Cancer
30/09/2019
TYME launched its multicenter randomized controlled pivotal stage of TYME-88-Panc trial for use of SM-88 in patients with third-line pancreatic cancer based on these clinical outcomes SM-88 is an oral, investigational [...]
ORYZON Presents Positive Efficacy Results on Iadademstat in ED-SCLC Patients at ESMO-2019
30/09/2019
75% of responses in the first 8 evaluable patients treated with the triple combination of iadademstat plus carboplatin-etoposide Main toxicity of the combination is hematological Iadademstat alone is safe, does not [...]
Further Data Review Shows Major Clinical Benefits From Veyonda®
30/09/2019
Comparative data shows Veyonda® significantly boosts the effectiveness of a promising new form of radiation therapy ( 177 LuPSMA) in advanced prostate cancer 177 LuPSMA therapy is the subject of a recent US$6 billion [...]
Kaleido Biosciences Announces Appointment of Jean Mixer to its Board of Directors
30/09/2019
LEXINGTON, Mass., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ to treat disease and [...]
Intra-Cellular Therapies to Present at the 2019 Cantor Global Healthcare Conference
30/09/2019
NEW YORK, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today [...]
CymaBay Therapeutics to Present at the 2019 Cantor Global Healthcare Conference
30/09/2019
NEWARK, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients [...]
Krystal Biotech to Present at the Cantor 2019 Global Healthcare Conference and Chardan's 3rd Annual Genetic Medicines Conference
30/09/2019
PITTSBURGH, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from skin [...]
BioSig to Present Clinical Observations at Venice Arrhythmias 2019
30/09/2019
Poster presentation to highlight initial clinical data collected with PURE EP(tm) System Westport, CT, Sept. 30, 2019 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM), a medical technology company developing [...]
Acarix publish EU growth prospectus in connection with rights issue of up to approximately SEK 51.8 million
30/09/2019
Press release Malmö, 30 September 2019 Acarix publish EU growth prospectus in connection with rights issue of up to approximately SEK 51.8 million The board of directors of Acarix AB ("Acarix" or the "Company") resolved [...]
T2 Biosystems’ T2Resistance™ Panel is Now Available as a Research Use Only (RUO) Test in the U.S.
30/09/2019
Panel is the only direct-from-blood diagnostic designed to detect genetic markers associated with antibiotic-resistant bloodstream infections LEXINGTON, Mass., Sept. 30, 2019 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. ( [...]
Idera Pharmaceuticals Announces Initiation of the ILLUMINATE-206 Trial Evaluating Tilsotolimod in Combination with Nivolumab and Ipilimumab for the Treatment of Solid Tumors
30/09/2019
EXTON, Pa., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) announced today the initiation of a phase 2 trial, ILLUMINATE-206 which will evaluate tilsotolimod, a toll-like receptor 9 (TLR9 [...]
Translate Bio to Present at the 3rd Annual Chardan Genetic Medicines Conference
30/09/2019
LEXINGTON, Mass., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat [...]
Checkpoint Therapeutics Announces Presentation of Positive Interim Clinical Results for Anti-PD-L1 Cosibelimab at the European Society for Medical Oncology (ESMO) Congress 2019
30/09/2019
50% objective response rate observed in cutaneous squamous cell carcinoma (CSCC) 40% objective response rate observed in non-small cell lung cancer Well-tolerated safety profile across all cohorts Enrollment ongoing to [...]
Resverlogix Announces Topline Results in BETonMACE Phase 3 Epigenetics Trial
30/09/2019
BETonMACE did not meet the primary endpoint Apabetalone development to continue to be advanced by the Company based on BETonMACE results Primary results to be presented during a late-breaking science session at AHA 2019 [...]
Syneos Health Introduces New Book, Why We Resist: The Surprising Truths About Motivating Behavior Change
30/09/2019
Syneos Health Behavioral Scientist and Expert Communicator Team Up to Author Behavioral Insights Book – Proceeds Donated to The STARR Coalition MORRISVILLE, N.C., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Syneos Health ® ( [...]
TG Therapeutics Announces Publication of Clinical Data from the Phase I/Ib Combination Trial of Ublituximab and Umbralisib (“U2”) in Blood
30/09/2019
U2 combination was generally well-tolerated with relatively low rates of immune-mediated toxicities Combination treatment resulted in median progression free survival (PFS) of ~28 months in relapsed/refractory chronic [...]
CK Hutchison offers 1.3% of Chi-Med’s share capital aiming to deconsolidate and hold Chi-Med as a strategic investment for the long term
30/09/2019
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION LONDON, Sept. 30, 2019 (GLOBE [...]

Pages